Parametric Portfolio Associates’s Corbus Pharmaceuticals CRBP Stock Holding History

Parametric Portfolio Associates’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-353	Closed	-$7K	–	3691
2021 Q4	$7K	Buy	+353	New	+$9.56K	﹤0.01%	3626
2021 Q3	–	Sell	-2,061	Closed	-$113K	–	3613
2021 Q2	$113K	Buy	2,061 +1,152	+127%	+$63.9K	﹤0.01%	3472
2021 Q1	$54K	Sell	909 -17	-2%	-$1.12K	﹤0.01%	4017
2020 Q4	$35K	Sell	926 -1,698	-65%	-$63.5K	﹤0.01%	3962
2020 Q3	$142K	Sell	2,624 -986	-27%	-$179K	﹤0.01%	3734
2020 Q2	$909K	Buy	3,610 +1,533	+74%	+$310K	﹤0.01%	2965
2020 Q1	$327K	Buy	2,077 +1,239	+148%	+$209K	﹤0.01%	3373
2019 Q4	$137K	Buy	838 +313	+60%	+$46.3K	﹤0.01%	3812
2019 Q3	$77K	Sell	525 -67	-11%	-$11.7K	﹤0.01%	3870
2019 Q2	$123K	Buy	+592	New	+$127K	﹤0.01%	3814

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Parametric Portfolio Associates's CRBP Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Corbus Pharmaceuticals (CRBP) in Q1 2022, closing a stake of 353 shares — an estimated $7K sold.

Parametric Portfolio Associates first reported a position in CRBP in Q2 2019 and held it in 10 quarters. The position peaked at $909K in Q2 2020. 72 funds tracked by Wall St. Rank hold CRBP as of Q1 2022.

Parametric Portfolio Associates reported no remaining Corbus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Parametric Portfolio Associates sold 353 Corbus Pharmaceuticals shares in Q1 2022, an estimated $7K.
Parametric Portfolio Associates first reported a position in Corbus Pharmaceuticals in Q2 2019 and held it in 10 quarters.
Parametric Portfolio Associates's Corbus Pharmaceuticals position peaked at $909K in Q2 2020.
72 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.